Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00476112 · ClinicalTrials.gov registry record · Phase 2
A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter
A Phase 2 study of Atrial Flutter, sponsored by Advanz Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT00476112 is a Phase 2 study of Atrial Flutter that has completed, run by Advanz Pharma. The registered enrollment target is 60 participants, below the 2,121-participant average among 23 other Atrial Flutter trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT00476112, a Phase 2 study of Atrial Flutter, has completed, sponsored by Advanz Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will attempt to demonstrate the effectiveness of RSD1235 in the conversion of atrial flutter (AFL) to sinus rhythm.
Conditions Studied
Interventions
- DRUG Vernakalant Injection 20 mg/mL
Study Locations (20)
Other
- Aalborg University - Aalborg
- H:S Bispebjerg Hospital - Copenhagen
- Centralsygehuset Esbjerg Varde - Esbjerg
- Glostrup Amtssygehus - Glostrup Municipality
- Gentofte Amtssygehus - Hellerup
- Herlev Amtssygehus, Kardiologisk - Herlev
- Sygehus Vendsyssel Hjorring - Hjørring
Alberta
- Heart Health Institute, Rockyview General Hospital - Calgary
- University of Calgary - Calgary
- University of Alberta Hospital - Edmonton
Quebec
- Institut de Cardiologie de Montreal - Montreal
- Hopital Notre-Dame du CHUM - Montreal
- CHUM-Hotel-Dieu de Montreal - Montreal
Virginia
- Medical College of Virginia - Richmond
- McGuire VA Medical Center - Richmond
Ontario
- Hamilton Health Sciences, Hamilton General Hospital - Hamilton
- Ottawa Hospitals (Civic & General) - Ottawa
California
- Regional Cardiology Associates - Sacramento
Michigan
- Thoracic and Cardiovascular Institute - Lansing
Wisconsin
- Marshfield Clinic - Marshfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-08 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00476112
The ClinicalTrials.gov registry entry for NCT00476112 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,121-participant average among 23 other Atrial Flutter trials with a reported enrollment target (97% lower). The listed sponsor is Advanz Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Flutter appearing as the primary indexed condition, and to 1 intervention - of which Vernakalant Injection 20 mg/mL is the first listed.
NCT00476112 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Alberta, Quebec.
Frequently Asked Questions
What is clinical trial NCT00476112 about?
NCT00476112 is a clinical study titled "A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter". This study will attempt to demonstrate the effectiveness of RSD1235 in the conversion of atrial flutter (AFL) to sinus rhythm.
What is the current status of trial NCT00476112?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2003-08. Estimated completion is 2004-09.
What conditions does trial NCT00476112 study?
This clinical trial studies the following conditions: Atrial Flutter.
What interventions are being tested in trial NCT00476112?
The interventions under investigation include: Vernakalant Injection 20 mg/mL (DRUG).
Who is sponsoring clinical trial NCT00476112?
This trial is sponsored by Advanz Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00476112 being conducted?
This trial has 20 study locations across California, Michigan, Virginia, Wisconsin, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Flutter
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter
COMPLETED · Phase 2
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
Get With the Guidelines Atrial Fibrillation Registry
RECRUITING
-
The Z Stitch Early Bed Rest Assessment Study
RECRUITING · NA
-
Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
RECRUITING
-
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.